糖尿病患者福音，基因编辑恢复自主胰岛素生产

Group 1 - The core point of the article highlights the successful transplantation of genetically modified islet cells in a patient with type 1 diabetes, restoring his ability to produce insulin autonomously, marking a significant advancement in gene editing technology [1] - This gene editing technique, particularly using CRISPR, has rapidly developed and expanded its application from single-gene hereditary diseases to over 6,000 diseases, indicating a growing trend in human gene therapy [1] - If this therapy is successfully promoted, it could fundamentally change the management of type 1 diabetes, alleviating the burden of daily insulin injections and frequent blood sugar monitoring for patients [1] Group 2 - Related A-share concept stocks include Beirui Gene and Guanhao Biological [2]